<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-167306" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hemangioblastoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khan</surname>
            <given-names>Muhammad M.</given-names>
          </name>
          <aff>National University of Science and Technology</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Belkhair</surname>
            <given-names>Sirajeddin</given-names>
          </name>
          <aff>Qatar University, Weill Cornell University (Doha campus), Hamad General Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Khan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sirajeddin Belkhair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-167306.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hemangioblastomas are rare, benign, highly vascularized tumors classified as WHO grade 1, primarily affecting the central nervous system. They most commonly occur in the cerebellum, followed by the spinal cord and brainstem. These tumors can be sporadic or associated with von Hippel-Lindau (VHL) disease, an autosomal dominant genetic disorder that predisposes individuals to various tumors.<xref ref-type="bibr" rid="article-167306.r1">[1]</xref><xref ref-type="bibr" rid="article-167306.r2">[2]</xref>&#x000a0;Approximately&#x000a0;45% of people with VHL disease develop CNS hemangioblastomas, and an estimated 20% of those with CNS hemangioblastomas have concurrent VHL disease.<xref ref-type="bibr" rid="article-167306.r3">[3]</xref><xref ref-type="bibr" rid="article-167306.r4">[4]</xref>&#x000a0;Hemangioblastomas are uncommon, representing 1% to 2.5% of all brain tumors and 2% to 10% of spinal cord tumors, typically manifesting between the ages of 30 and 60, with a slight male predominance.<xref ref-type="bibr" rid="article-167306.r5">[5]</xref><xref ref-type="bibr" rid="article-167306.r6">[6]</xref></p>
        <p>The clinical presentation of hemangioblastomas varies depending on their location and can&#x000a0;significantly impact the quality of life. Cerebellar tumors often cause headaches, nausea, vomiting, and signs of increased intracranial pressure, while brainstem tumors can lead to motor and sensory deficits, ataxia, and potentially fatal hemorrhages. Spinal hemangioblastomas may result in localized pain, motor weakness, sensory disturbances, and bowel or bladder dysfunction.<xref ref-type="bibr" rid="article-167306.r6">[6]</xref></p>
        <p>Diagnosis is primarily made through magnetic resonance imaging, which typically reveals a cystic mass with an enhancing mural nodule. The primary treatment is surgical resection, with preoperative embolization sometimes necessary due to the tumor's vascularity. Stereotactic radiosurgery and novel agents targeting vascular endothelial growth factor pathways are emerging treatments for multiple or surgically inaccessible tumors.<xref ref-type="bibr" rid="article-167306.r7">[7]</xref><xref ref-type="bibr" rid="article-167306.r8">[8]</xref> The prognosis after surgery is generally favorable, with low recurrence rates of less than 25%, although regular follow-up is crucial, especially in patients with VHL disease.<xref ref-type="bibr" rid="article-167306.r9">[9]</xref></p>
      </sec>
      <sec id="article-167306.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hemangioblastoma can occur sporadically (75%) or in association with VHL disease. VHL is caused by a germline mutation of the <italic toggle="yes">VHL</italic> gene inherited in an autosomal dominant fashion. However, somatic mutations of <italic toggle="yes">VHL</italic>, amongst other genomic aberrations, have been identified in sporadic cases.<xref ref-type="bibr" rid="article-167306.r10">[10]</xref><italic toggle="yes">&#x000a0;VHL</italic> is a tumor-suppressor gene located on chromosome 3p25-26 that encodes VHL protein (pVHL) of 213 amino acids. Identified <italic toggle="yes">VHL</italic> gene alterations include missense, splice-site, and frameshift (deletions &#x0003e; insertions) mutations, as well as epigenetic suppression of <italic toggle="yes">VHL</italic> through promoter methylation.<xref ref-type="bibr" rid="article-167306.r10">[10]</xref><xref ref-type="bibr" rid="article-167306.r11">[11]</xref><xref ref-type="bibr" rid="article-167306.r12">[12]</xref>&#x000a0;<italic toggle="yes">VHL</italic> mutation or deletion is more common in VHL-associated hemangioblastomas, whereas promoter methylation has only been detected in sporadic cases.&#x000a0;In addition, loss of heterozygosity in chromosomes 6 and 10, even in the absence of <italic toggle="yes">VHL</italic> mutation, has been identified in sporadic cases, suggesting alternative pathways for sporadic disease development.<xref ref-type="bibr" rid="article-167306.r10">[10]</xref></p>
      </sec>
      <sec id="article-167306.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hemangioblastomas contribute to approximately 1% to 2.5% of all intracranial tumors and about 2% to 10% of primary spinal cord tumors. The overall incidence rate of CNS hemangioblastomas is approximately 0.141 per 100,000 person-years. These tumors are rare, with only 1 person out of a million estimated to develop hemangioblastomas each year. They are more commonly diagnosed in adults between the ages of 30 and 65, with a slight predominance in males. The male-to-female ratio ranges from 1.3:1 to 2.6:1.<xref ref-type="bibr" rid="article-167306.r9">[9]</xref><xref ref-type="bibr" rid="article-167306.r13">[13]</xref></p>
        <p>
<bold>Anatomic Distribution</bold>
</p>
        <p>Although they can occur anywhere in the central nervous system, most hemangioblastomas arise in the posterior fossa of the brain, with the cerebellum being the most common site. Approximately 45% to 50% of these tumors are found in the cerebellum, 30% to 40% in the spinal cord, and 5% to 10% in the brainstem.<xref ref-type="bibr" rid="article-167306.r14">[14]</xref>&#x000a0;Sporadic hemangioblastomas are typically solitary; multiple tumors within the neuraxis should raise suspicion for VHL disease. In patients with sporadic hemangioblastomas, isolated cerebellar lesions are more common. However, individuals with VHL may have multiple lesions in the spinal cord, cerebellum, and brainstem.<xref ref-type="bibr" rid="article-167306.r9">[9]</xref></p>
      </sec>
      <sec id="article-167306.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pVHL plays an essential role in cell cycle regulation and is involved in the degradation of hypoxia-inducible factors. Amongst several downstream targets, hypoxia-inducible factors are known to activate the transcription of erythropoietin, vascular endothelial growth factor, and platelet-derived growth factor in hypoxic conditions. Loss of pVHL function mimics hypoxia, and consequently, cells are unable to degrade hypoxia-inducible factors despite the presence of oxygen.<xref ref-type="bibr" rid="article-167306.r15">[15]</xref>&#x000a0;This results in the upregulation of downstream targets, contributing to the characteristic hypervascularity and erythropoietin overproduction of hemangioblastoma tumors. The 2-hit theory of biallelic inactivation of the <italic toggle="yes">VHL</italic> gene is thought to initiate tumorigenesis.&#x000a0;</p>
        <p>In VHL syndrome, affected organs reveal microscopic developmental changes and the formation of preneoplastic lesions. Precursor cells are developmentally arrested in hemangioblasts that have biallelic <italic toggle="yes">VHL</italic> inactivation. However, these cells begin to cause reactive angiogenesis through unknown triggering mechanisms, and a subset may grow faster, progressing to hemangioblastoma. During growth, hemangioblastoma cells imitate the morphology of embryonic hemangioblasts, the precursors of hematopoietic and endothelial cells.<xref ref-type="bibr" rid="article-167306.r16">[16]</xref></p>
      </sec>
      <sec id="article-167306.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The hallmark histological feature of hemangioblastomas is their biphasic tissue composition comprising stromal cells and capillary networks. Stromal cells, which are large and polygonal, compose the neoplastic element, driving tumor growth and neovascularization. They have clear cytoplasm full of lipid vacuoles, giving them a foamy look with round or oval nuclei and prominent nucleolus.<xref ref-type="bibr" rid="article-167306.r13">[13]</xref>&#x000a0;The vascular component of hemangioblastomas has dense capillary networks and sinusoids. These blood vessels have a single layer of endothelial cells that are often dilated, contributing to the tumor's highly vascular nature (see <bold>Image.</bold> Hemangioblastoma). The vascular structure helps the tumor grow by supplying nutrients and oxygen. Additionally, these capillaries have pericytes and smooth muscle cells which provide structural support.<xref ref-type="bibr" rid="article-167306.r13">[13]</xref></p>
        <p>Immunohistochemical staining is crucial in helping to differentiate hemangioblastomas from other central nervous system (CNS) tumors. Stromal cells in hemangioblastomas show several markers, including alpha-inhibin, S100 protein, and vimentin. Alpha-inhibin helps distinguish hemangioblastomas from metastatic clear cell renal cell carcinoma, which can have a similar microscopic appearance. In addition, stromal cells are negative for epithelial markers like cytokeratin, typically noted in clear cell renal cell carcinoma. Endothelial markers (eg, CD31 and CD34) highlight the tumor's vascular network.<xref ref-type="bibr" rid="article-167306.r17">[17]</xref></p>
      </sec>
      <sec id="article-167306.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Clinical History</bold>
</p>
        <p>Hemangioblastoma evaluation begins with a comprehensive history and thorough physical examination, which guides the physician to an intracranial pathology. In patients with hemangioblastoma, clinical presentation depends upon the location of the tumor and compressed areas. Clinical symptoms result once these slow-growing tumors have exerted enough of a significant mass effect to disrupt the function of the surrounding area. The most common location for these tumors is the posterior fossa, which causes an obstructive effect on the fourth ventricle or the cerebral aqueduct and increases intracranial pressure, which presents with symptoms such as headache and vomiting. Additionally, patients may report dizziness, ataxia, and gait disturbances due to compromised balance and coordination functions.<xref ref-type="bibr" rid="article-167306.r1">[1]</xref><xref ref-type="bibr" rid="article-167306.r2">[2]</xref>&#x000a0;Brainstem hemangioblastomas present with motor and sensory deficits, nausea, vomiting, ataxia, and sometimes fatal hemorrhage. Spinal hemangioblastomas, on the other hand, can cause localized pain, motor weakness, sensory disturbances, and bowel or bladder dysfunction.</p>
        <p>A thorough family history is advised to identify incidents that may indicate a genetic linkage. Personal or family history may reveal VHL-related tumors, including retinal angiomas, also called benign vascular hamartomas, clear cell renal cell carcinomas, pheochromocytomas, and pancreatic neuroendocrine neoplasms. Additionally, a history of VHL-related tumor&#x000a0;surgical resection in the patient or a family member is relevant.<xref ref-type="bibr" rid="article-167306.r3">[3]</xref><xref ref-type="bibr" rid="article-167306.r4">[4]</xref></p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>In patients with hemangioblastomas, typical findings include signs of increased intracranial pressure and cerebral mass effect. Additional examination findings vary depending on the tumor location within the CNS.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref>&#x000a0;Neurological examination is essential for assessing the impact of the tumor on various CNS functions. The following findings are associated with hemangioblastomas located in these CNS areas:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ataxia</bold>: Difficulty with coordination and balance that leads to gait disturbances and difficulty performing delicate motor tasks.</p>
          </list-item>
          <list-item>
            <p><bold>Dysmetria</bold>:&#x000a0;Dysmetria is tested using finger-to-nose or heel-to-shin tests and is primarily present with tumors located in the cerebellum.</p>
          </list-item>
          <list-item>
            <p><bold>Nystagmus:</bold>&#x000a0;Cerebellar or brainstem involvement may indicated by nystagmus.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Back Pain:</bold> Localized or radicular back pain may radiate along the distribution of the affected nerve roots.</p>
          </list-item>
          <list-item>
            <p><bold>Motor weakness and myelopathy: </bold>Weakness commonly arises in the muscles innervated by the affected spinal level.</p>
          </list-item>
          <list-item>
            <p><bold>Sensory Disturbances:</bold> Loss of sensation or paresthesias in the dermatomes typically corresponds to the involved spinal levels.<xref ref-type="bibr" rid="article-167306.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;Additionally, a&#x000a0;systemic examination is warranted in patients with VHL disease to identify other syndrome manifestations, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Abdominal examination:</bold> To detect masses suggestive of renal cell carcinoma or pancreatic tumors</p>
          </list-item>
          <list-item>
            <p><bold>Ophthalmologic examination:</bold>&#x000a0;To exclude retinal lesions</p>
          </list-item>
          <list-item>
            <p><bold>Endocrine evaluation:</bold>&#x000a0;To assess for symptoms of pheochromocytoma (eg, hypertension, palpitations, and episodic headaches)&#x000a0;<xref ref-type="bibr" rid="article-167306.r4">[4]</xref><xref ref-type="bibr" rid="article-167306.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-167306.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Diagnostic Imaging Studies</bold>
</p>
        <p>Clinical findings can guide clinicians in determining the optimal imaging study for the diagnostic evaluation of a suspected tumor.</p>
        <p>
<bold>Magnetic resonance imaging</bold>
</p>
        <p>Magnetic resonance imaging (MRI) is the preferred modality for diagnosing CNS hemangioblastomas due to its detailed visualization of CNS structures. A characteristic MRI finding of hemangioblastomas is a&#x000a0;mural nodule within a cyst. This feature typically appears as a well-circumscribed lesion enhanced by contrast with an associated cystic component.<xref ref-type="bibr" rid="article-167306.r6">[6]</xref><xref ref-type="bibr" rid="article-167306.r18">[18]</xref>&#x000a0;The following findings are frequently observed in&#x000a0;hemangioblastoma MRIs:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>T1:</bold> The mural nodule appears hypointense to isointense. The cyst content shows a signal similar to cerebrospinal fluid.</p>
          </list-item>
          <list-item>
            <p><bold>T1 with contrast:</bold> The mural nodule shows vivid enhancement with gadolinium contrast; however, the cyst wall does not enhance (see <bold>Images</bold>. Axial MRI Head With Contrast and Sagittal&#x000a0;MRI Head With Contrast).</p>
          </list-item>
          <list-item>
            <p><bold>T2:</bold> The mural nodule appears hyperintense. Flow voids,&#x000a0;seen in 60% to 70% of cases, occur due to enlarged vessels, especially at the periphery of the cyst. The cyst is fluid-filled and has a signal similar to cerebrospinal fluid.</p>
          </list-item>
          <list-item>
            <p><bold>MR perfusion</bold>: High relative cerebral blood volume ratios are better observed with this study.</p>
          </list-item>
        </list>
        <p>
<bold>Computed tomography imaging</bold>
</p>
        <p>In computed tomography (CT) studies, the mural nodule in hemangioblastomas appears isodense to the brain on noncontrast images surrounded by cystic fluid. The mural nodule also demonstrates intense homogeneous enhancement (see&#x000a0;<bold>Image</bold>. Computed tomography With Contrast). The cyst walls usually do not enhance. Calcification is not present in these tumors.<xref ref-type="bibr" rid="article-167306.r6">[6]</xref></p>
        <p>
<bold>Angiography</bold>
</p>
        <p>Studies using angiography facilitate visualization of enlarged feeding arteries and dilated draining veins often seen in hemangioblastomas. A dense tumor blush is commonly observed centrally, demonstrating the tumor's rich blood supply.<xref ref-type="bibr" rid="article-167306.r6">[6]</xref></p>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>Laboratory studies are primarily performed for preoperative evaluation to assess the patient's overall health and readiness for surgery, including complete blood count, liver function tests, renal function tests, and coagulation profiles.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref>&#x000a0;In cases where hemangioblastoma is associated with Von Hippel Lindau disease, genetic testing for <italic toggle="yes">VHL</italic> gene mutation is recommended.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref></p>
      </sec>
      <sec id="article-167306.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>Surgical resection is the treatment of choice for CNS hemangioblastoma, especially for symptomatic tumors secondary to mass effect. The goal of the surgery is complete tumor removal while minimizing damage to surrounding neural structures. Due to the high vascularity of such tumors, preoperative planning is essential to minimize intraoperative bleeding. Preoperative embolization can be considered to reduce the tumor's blood supply and facilitate safer resection. As most tumors arise in the posterior fossa, the usual surgical approach is a suboccipital craniotomy, which provides an excellent corridor to resect this lesion.<xref ref-type="bibr" rid="article-167306.r2">[2]</xref> Microsurgical techniques are used to resect the tumor with the help of a microscope. Intraoperative neurophysiological monitoring can help preserve neurological function during spinal and cranial surgery. Image-guided navigation systems may also be used to improve the accuracy of tumor localization and resection.<xref ref-type="bibr" rid="article-167306.r2">[2]</xref></p>
        <p>
<bold>Medical Management</bold>
</p>
        <p>Medical management of CNS hemangioblastoma is usually supportive because these tumors are benign lesions that do not invade the surrounding structures or metastasize. Hence, chemotherapy has a limited role. Novel therapeutic agents, including antiangiogenic factors, have demonstrated promising results in managing these tumors, especially in patients with<italic toggle="yes"> VHL</italic> gene mutations.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref>&#x000a0;Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor and has been investigated for its ability to inhibit tumor growth by reducing angiogenesis. Other tyrosine kinase inhibitors (eg, sunitinib and sorafenib) have also been explored for their antiangiogenic properties.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref><xref ref-type="bibr" rid="article-167306.r8">[8]</xref></p>
        <p>
<bold>Radiation Therapy</bold>
</p>
        <p>Stereotactic radiosurgery (SRS) is a noninvasive treatment option that delivers high doses of radiation precisely to the tumor while sparing surrounding healthy tissue. SRS is beneficial for small, inaccessible hemangioblastomas or residual tumors following surgery. Gamma knife and CyberKnife are common modalities used for SRS.<xref ref-type="bibr" rid="article-167306.r19">[19]</xref></p>
        <p>
<bold>Tumor Surveillance</bold>
</p>
        <p>Regular follow-up with MRI is essential for detecting tumor recurrence or progression. The follow-up imaging duration varies based on the initial tumor characteristics, including the extent of resection achieved and the presence of <italic toggle="yes">VHL</italic> mutation. MRI scans are usually done every 6 to 12 months postoperatively for the first few years and then yearly if no recurrence is detected.<xref ref-type="bibr" rid="article-167306.r9">[9]</xref></p>
        <p>Similar surveillance is recommended for VHL disease. A follow-up assessment is essential due to the risk of tumor recurrence or the development of new lesions. Follow-up usually includes regular imaging as well as ophthalmologic examination for retinal hemangioblastomas. Genetic counseling and testing are recommended for patients and their families to identify at-risk individuals and implement early surveillance strategies.<xref ref-type="bibr" rid="article-167306.r4">[4]</xref><xref ref-type="bibr" rid="article-167306.r12">[12]</xref></p>
      </sec>
      <sec id="article-167306.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Metastatic Carcinoma</bold>
</p>
        <p>Metastatic brain tumors from various primaries, especially renal cell carcinoma, can easily mimic hemangioblastomas in the posterior fossa of the brain. Metastatic lesions are the most common lesions in the posterior fossa of the brain. Renal cell carcinoma closely resembles hemangioblastomas, both radiologically and histologically. Renal cell carcinoma metastasis can present as a well-circumscribed hypervascular lesion with similar clear cell morphology. Immunohistochemical staining is needed to differentiate between both pathologies. Hemangioblastomas typically express alpha-inhibin and S100 protein, while RCC metastases express epithelial markers such as cytokeratin and epithelial membrane antigen.<xref ref-type="bibr" rid="article-167306.r20">[20]</xref><xref ref-type="bibr" rid="article-167306.r21">[21]</xref></p>
        <p>
<bold>Pilocytic Astrocytoma</bold>
</p>
        <p>Pilocytic astrocytoma is a common benign tumor in children and young adults. Radiographically, it can present with cystic and solid components similar to hemangioblastomas. Both lesions are well-circumscribed and can be enhanced with contrast. On histopathological examination, pilocytic astrocytomas show Rosenthal fibers and eosinophilic granular bodies, which are absent in hemangioblastomas. Immunohistochemical staining can further help differentiate hemangioblastomas from pilocytic astrocytomas, which usually express <italic toggle="yes">GFAP</italic>.<xref ref-type="bibr" rid="article-167306.r22">[22]</xref>&#x000a0;(see<bold>&#x000a0;Image</bold>. Pilocytic Astrocytoma).</p>
        <p>
<bold>Ependymoma</bold>
</p>
        <p>Ependymomas arise from the fourth ventricle lining. Due to the similar location and sometimes cystic appearance, ependymomas can be confused with hemangioblastomas. Ependymomas are differentiated from hemangioblastomas by the characteristic perivascular pseudorosettes and ependymal rosettes. In addition, ependymomas express GFAP and EMA, which are absent in hemangioblastomas.<xref ref-type="bibr" rid="article-167306.r22">[22]</xref><xref ref-type="bibr" rid="article-167306.r23">[23]</xref></p>
        <p>
<bold>Vascular Malformations</bold>
</p>
        <p>Vascular lesions such as arteriovenous malformations and cavernous malformations can mimic these lesions on imagining due to their high vascular nature. Arteriovenous malformations on imaging have a nidus with direct arteriovenous shunting, while cavernous malformations consist of dilated and thin-walled capillaries without intervening brain tissue. These features distinguish vascular lesions from the organized capillary network and stromal cells of hemangioblastomas and, in most cases, the cystic lesion. Imaging modalities (eg, MRI and angiography) can aid in identifying these vascular malformations.<xref ref-type="bibr" rid="article-167306.r24">[24]</xref></p>
        <p>
<bold>Other Cystic Lesions</bold>
</p>
        <p>Other CNS cystic lesions, such&#x000a0;as arachnoid cysts and neuroenteric cysts, should be considered as differential diagnoses when present in the cerebellum. Arachnoid cysts are benign with fluid-filled sacs that arise within the arachnoid membrane and are generally asymptomatic unless they are large in size and cause symptoms related to mass effect. Unlike hemangioblastomas, they do not enhance with contrast on MRI. Neuroenteric cysts are rare congenital lesions that can also appear cystic but have distinct histological features, including a lining of gastrointestinal or respiratory epithelium.<xref ref-type="bibr" rid="article-167306.r25">[25]</xref></p>
      </sec>
      <sec id="article-167306.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>
<bold>Radiation Therapy Planning</bold>
</p>
        <p>Treatment planning is a necessary process wherein a patient's clinical presentation and images must be studied for the best outcomes. Therapy planning considers several factors, including tumor size, location, vascularity, and the patient's overall health. Because these tumors are highly vascular, the treatment plans must be precise and individualized to optimize outcomes and minimize complications.</p>
        <p>
<bold>Simulation imaging</bold>
</p>
        <p>Simulation imaging is a process that uses imaging to plan for radiation by defining the treatment area and preparing the radiation delivery. A CT scan is performed with the patient in the treatment position, thus providing detailed anatomical information and helping to outline the tumor and surrounding structures. MRI is often combined with CT images to enhance soft tissue contrast and further improve the accuracy of tumor delineation.&#x000a0;This combination is especially important for CNS tumors where precise targeting is critical to avoid damaging healthy brain tissue.<xref ref-type="bibr" rid="article-167306.r26">[26]</xref></p>
        <p>After the simulation is complete and the tumor margins are perfectly delineated, treating clinicians assess the target volumes for the radiation therapy. The gross tumor volume includes the visible tumor in imaging studies. The clinical target volume encompasses the gross tumor and any potential microscopic disease spread. The planning target volume adds margin to the clinical target volume to compensate for patient movement or other variations and uncertainties in radiation delivery. This ensures that the prescribed dose covers the target area despite these variables.<xref ref-type="bibr" rid="article-167306.r26">[26]</xref></p>
        <p>Radiation therapy for hemangioblastomas primarily involves SRS. Other common methods include Gamma knife, CyberKnife, and Linear Accelerator with Gamma knife being the most published method for treating hemangioblastoma. Different authors have mentioned different target volumes for radiation therapy that change from center to center. Median marginal doses for SRS range from 12 to 29.9 Gy, with a maximum dose of 13.3 to 40 Gy. Median isodose lines vary between 50% and 90%. Follow-up periods range from 12 to 102 months. This shows satisfactory tumor control rates with pooled 5-year progression-free survival of around 88.4%.<xref ref-type="bibr" rid="article-167306.r27">[27]</xref><xref ref-type="bibr" rid="article-167306.r28">[28]</xref><xref ref-type="bibr" rid="article-167306.r29">[29]</xref><xref ref-type="bibr" rid="article-167306.r30">[30]</xref></p>
        <p>SRS is recommended for incompletely resected and recurrent tumors and is also suitable for patients with unfavorable anatomy for surgical resection or medical comorbidities, which makes surgery risky. Patients with VHL disease who have had multiple prior surgical resections are usually good candidates for SRS. Common adverse effects include hydrocephalus, radiation necrosis, peritumoral edema, headache, nausea, and vomiting. Tumor control rates are 92% at 3 years, 89% at 5 years, and 79% at 10 years. Overall survival rates are 94% at 3 years, 90% at 5 years, and 74% at 10 years.<xref ref-type="bibr" rid="article-167306.r29">[29]</xref><xref ref-type="bibr" rid="article-167306.r30">[30]</xref><xref ref-type="bibr" rid="article-167306.r31">[31]</xref></p>
        <p>Various studies report a range of radiation doses for hemangioblastoma treatment via SRS. The dose falls between 14 and 35 Gy, with a median dose around 18 to 21 Gy. Dose selection will depend on factors like tumor size and location and patient factors such as age and overall health. Smaller tumors receive higher doses per fraction. Doses near critical structures like the brainstem or optic nerves need careful planning to minimize side effects. SRS is a single-fraction treatment where the entire radiation dose is delivered in a single session. The treatment takes only a few minutes, but the planning and preparation process can take several hours. The long-term effects of SRS are still under investigation. These patients need Regular follow-up MRIs to monitor for tumor control and potential side effects of the radiation therapy.<xref ref-type="bibr" rid="article-167306.r32">[32]</xref><xref ref-type="bibr" rid="article-167306.r33">[33]</xref></p>
      </sec>
      <sec id="article-167306.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of patients with hemangioblastoma depends on numerous factors, including the location of the tumor, its size at the time of presentation, and whether it is sporadic or associated with VHL disease. Postoperatively, the success of the surgery and the extent of resection will help determine the patient's prognosis.&#x000a0;In&#x000a0;sporadic hemangioblastomas that are not linked to any genetic syndrome, the prognosis is usually excellent after complete surgical resection. These tumors grow slowly; complete resection often leads to long-term disease-free survival. Recurrence rates are low if the tumor is completely removed. Studies show that patients with sporadic hemangioblastomas have a high long-term survival rate, with a 5-year survival rate exceeding 90%.<xref ref-type="bibr" rid="article-167306.r1">[1]</xref><xref ref-type="bibr" rid="article-167306.r4">[4]</xref><xref ref-type="bibr" rid="article-167306.r9">[9]</xref>&#x000a0;The prognosis of patients with VHL is more varied and complex as patients can have other tumors like renal cell carcinoma, pheochromocytoma, and pancreatic tumors. When such patients develop CNS involvement, their outcome tends to be worse.<xref ref-type="bibr" rid="article-167306.r3">[3]</xref><xref ref-type="bibr" rid="article-167306.r4">[4]</xref></p>
      </sec>
      <sec id="article-167306.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Hemangioblastomas in the cerebellum or brainstem can obstruct the cerebrospinal fluid pathways, which can cause hydrocephalus, necessitating further surgical interventions such as having a ventriculoperitoneal shunt or third ventriculostomy. Tumors in distinct locations lead to specific neurological deficits: cerebellar tumors cause cerebellar signs, spinal cord tumors result in motor weakness and sensory disturbances, and brainstem tumors affect cranial nerves, causing symptoms like facial weakness, dysphagia, and diplopia.<xref ref-type="bibr" rid="article-167306.r1">[1]</xref><xref ref-type="bibr" rid="article-167306.r2">[2]</xref><xref ref-type="bibr" rid="article-167306.r4">[4]</xref><xref ref-type="bibr" rid="article-167306.r14">[14]</xref></p>
        <p>Surgical resection of hemangioblastomas carries a considerable risk of significant intraoperative bleeding due to their rich vascular supply. Preoperative embolization can reduce but not eliminate this risk. Complete resection is challenging, especially in critical areas like the brainstem and spinal cord, and can result in postoperative complications such as new or worsened neurological deficits. Surgery in the posterior fossa also carries the risk of cerebrospinal fluid leak, which can lead to meningitis if not managed promptly. Adequate closure techniques and vigilant postoperative monitoring are essential.<xref ref-type="bibr" rid="article-167306.r2">[2]</xref><xref ref-type="bibr" rid="article-167306.r18">[18]</xref></p>
        <p>Patients with VHL&#x000a0;disease are at high risk for multiple lesions and tumor recurrence, requiring regular MRI surveillance. Recurrence or new tumors might necessitate repeated surgeries, increasing the cumulative risk of complications. This genetic disease is also linked to other neoplasms like pheochromocytomas, renal cell carcinoma, and pancreatic neuroendocrine tumors, leading to complications such as hypertension and renal dysfunction. A multidisciplinary approach is essential for managing these issues. The chronic nature of the disease and ongoing surveillance impact patients' quality of life, thus making psychological support and rehabilitation services crucial.<xref ref-type="bibr" rid="article-167306.r5">[5]</xref><xref ref-type="bibr" rid="article-167306.r4">[4]</xref><xref ref-type="bibr" rid="article-167306.r16">[16]</xref></p>
      </sec>
      <sec id="article-167306.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Like any other disease, patient education is crucial, especially in patients with von Hippel Landau disease. These patients must understand that they have a critical condition with some genetic predisposition that makes them vulnerable to other tumors in other parts of the body. A&#x000a0;regularly scheduled MRI and imaging studies are essential to monitor tumors. Early detection and treatment are essential, and therefore, the patient should have adequate information about their disease and the genetic knowledge of their condition to help them recognize their symptoms early and plan their future accordingly, such as having genetic counseling before starting a family.</p>
      </sec>
      <sec id="article-167306.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective management of hemangioblastoma necessitates a cohesive interprofessional team involving physicians, advanced practitioners, nurses, pharmacists, and other health professionals. In collaboration with other specialists, neurosurgeons should regularly meet to develop and refine personalized treatment and follow-up surveillance plans, ensuring accurate and early diagnosis. Each patient&#x02019;s unique medical history, including family history, must be thoroughly evaluated. Interprofessional communication is critical in educating patients and their families about the disease and treatment options, empowering them to participate in care decisions, and improving outcomes. Physicians and surgeons must stay current with the latest research and guidelines, providing evidence-based care. Continuous quality improvement processes, alongside ongoing education and training for all healthcare professionals, are essential for enhancing patient-centered care, ensuring safety, and optimizing team performance.</p>
      </sec>
      <sec id="article-167306.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=167306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=167306">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/hemangioblastoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=167306">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/167306/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=167306">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-167306.s16">
        <fig id="article-167306.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Sagittal MRI Head With Contrast. Sagittal and axial MRI images show the mural nodule with vivid enhancement due to gadolinium contrast. Contributed by MM Khan, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sagital" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-167306.s17">
        <fig id="article-167306.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Axial MRI Head With Contrast. Axial MRI images show the mural nodule with vivid enhancement due to gadolinium contrast. Contributed by MM Khan, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="axial" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-167306.s18">
        <fig id="article-167306.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Computed tomography With Contrast. Sagittal view of a hemangioblastoma on computed tomography. Contributed by MM Khan, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ct" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-167306.s19">
        <fig id="article-167306.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Pilocytic Astrocytoma. Sagittal and axial MRI images show a left cystic lesion with an enhancing nodule. Contributed by MM Khan, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pa" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-167306.s20">
        <fig id="article-167306.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Hemangioblastoma.&#x000a0;Hemangioblastomas have a hallmark histological feature: their biphasic tissue composition comprising stromal cells and capillary networks. The vascular component of hemangioblastomas has dense capillary networks and sinusoids. These blood vessels have a single layer of endothelial cells that are often dilated, contributing to the tumor's highly vascular nature. Contributed by D Neelon, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Hemangioblastoma__HP" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-167306.s21">
        <title>References</title>
        <ref id="article-167306.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conway</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clatterbuck</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Brem</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rigamonti</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease.</article-title>
            <source>Neurosurgery</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-62; discussion 62-3</page-range>
            <pub-id pub-id-type="pmid">11152361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Br&#x000fc;ndl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;del</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ullrich</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Brawanski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schebesch</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Surgical resection of sporadic and hereditary hemangioblastoma: Our 10-year experience and a literature review.</article-title>
            <source>Surg Neurol Int</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>138</fpage>
            <pub-id pub-id-type="pmid">25317353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedrich</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Von Hippel-Lindau syndrome. A pleomorphic condition.</article-title>
            <source>Cancer</source>
            <year>1999</year>
            <month>Dec</month>
            <day>01</day>
            <volume>86</volume>
            <issue>11 Suppl</issue>
            <fpage>2478</fpage>
            <page-range>2478-82</page-range>
            <pub-id pub-id-type="pmid">10630173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganeshan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Menias</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Pickhardt</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sandrasegaran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lubner</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ramalingam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tumors in von Hippel-Lindau Syndrome: From Head to Toe-Comprehensive State-of-the-Art Review.</article-title>
            <source>Radiographics</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>849</fpage>
            <page-range>849-866</page-range>
            <pub-id pub-id-type="pmid">29601266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrukh</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Cerebellar hemangioblastoma presenting as secondary erythrocytosis and aspiration pneumonia.</article-title>
            <source>West J Med</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>164</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-71</page-range>
            <pub-id pub-id-type="pmid">8775737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Smirniotopoulos</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Rushing</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Radiologic-pathologic correlation: hemangioblastoma.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>1992</year>
            <season>Sep-Oct</season>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>1343</fpage>
            <page-range>1343-52</page-range>
            <pub-id pub-id-type="pmid">1414827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cvek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knybel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reguli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lipina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hanzlikova</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>&#x00160;ilh&#x000e1;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Resova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blazek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palicka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feltl</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up.</article-title>
            <source>Rep Pract Oncol Radiother</source>
            <year>2022</year>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>134</fpage>
            <page-range>134-141</page-range>
            <pub-id pub-id-type="pmid">35402025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mak</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Algird</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenspoon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Provias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirte</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cervicomedullary hemangioblastoma treated with bevacizumab.</article-title>
            <source>Neurooncol Adv</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>vdaa076</fpage>
            <pub-id pub-id-type="pmid">32908970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Incidence, Prognostic Factors and Survival for Hemangioblastoma of the Central Nervous System: Analysis Based on the Surveillance, Epidemiology, and End Results Database.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>570103</fpage>
            <pub-id pub-id-type="pmid">33014882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takayanagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukasa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Omata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ichimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakatomi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ueki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aburatani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.</article-title>
            <source>Neuro Oncol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>1228</fpage>
            <page-range>1228-1236</page-range>
            <pub-id pub-id-type="pmid">28379443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Graffeo</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Parney</surname>
                <given-names>IF</given-names>
              </name>
            </person-group>
            <article-title>Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas.</article-title>
            <source>J Neurooncol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>159</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-231</page-range>
            <pub-id pub-id-type="pmid">35902552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maher</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>von Hippel-Lindau disease: a clinical and scientific review.</article-title>
            <source>Eur J Hum Genet</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>617</fpage>
            <page-range>617-23</page-range>
            <pub-id pub-id-type="pmid">21386872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Meningeal supratentorial hemangioblastoma in a patient with von hippel-lindau disease mimicking angioblastic menigioma.</article-title>
            <source>J Korean Neurosurg Soc</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>415</fpage>
            <page-range>415-9</page-range>
            <pub-id pub-id-type="pmid">24379949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vetrano</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Gioppo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farag&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pinzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pollo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Broggi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schiariti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferroli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Acerbi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hemangioblastomas and Other Vascular Origating Tumors of Brain or Spinal Cord.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2023</year>
            <volume>1405</volume>
            <fpage>377</fpage>
            <page-range>377-403</page-range>
            <pub-id pub-id-type="pmid">37452946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiesener</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Eckardt</surname>
                <given-names>KU</given-names>
              </name>
            </person-group>
            <article-title>Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>356</fpage>
            <page-range>356-9</page-range>
            <pub-id pub-id-type="pmid">11865075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klingler</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gl&#x000e4;sker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bausch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Urbach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jilg</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Steiert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Puzik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neumann-Haefelin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kotsis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agostini</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>HPH</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment.</article-title>
            <source>Childs Nerv Syst</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>2537</fpage>
            <page-range>2537-2552</page-range>
            <pub-id pub-id-type="pmid">32507909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoda</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Neuropathologic features of central nervous system hemangioblastoma.</article-title>
            <source>J Pathol Transl Med</source>
            <year>2022</year>
            <month>May</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>115</fpage>
            <page-range>115-125</page-range>
            <pub-id pub-id-type="pmid">35501672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonneville</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sarrazin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Marsot-Dupuch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iffenecker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cordoliani</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Doyon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bonneville</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Unusual lesions of the cerebellopontine angle: a segmental approach.</article-title>
            <source>Radiographics</source>
            <year>2001</year>
            <season>Mar-Apr</season>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>419</fpage>
            <page-range>419-38</page-range>
            <pub-id pub-id-type="pmid">11259705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shuto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yomo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moriki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kenai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Duma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Akabane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nagano</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kondziolka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study.</article-title>
            <source>J Neurosurg</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>1469</fpage>
            <page-range>1469-78</page-range>
            <pub-id pub-id-type="pmid">25816088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Histologic variations and immunohistochemical features of metastatic clear cell renal cell carcinoma.</article-title>
            <source>Korean J Pathol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>426</fpage>
            <page-range>426-32</page-range>
            <pub-id pub-id-type="pmid">24255630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kojima</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Musangile</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Matsuzaki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yorita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nagashima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Current Knowledge and Prospects for Renal Hemangioblastoma and Renal Cell Carcinoma with Hemangioblastoma-like Features.</article-title>
            <source>Biomedicines</source>
            <year>2023</year>
            <month>May</month>
            <day>17</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37239138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suri</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Tatke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.</article-title>
            <source>Indian J Cancer</source>
            <year>2004</year>
            <season>Apr-Jun</season>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>66</fpage>
            <page-range>66-71</page-range>
            <pub-id pub-id-type="pmid">15318011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Louis</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reifenberger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>von Deimling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figarella-Branger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cavenee</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Ohgaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wiestler</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Kleihues</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.</article-title>
            <source>Acta Neuropathol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>803</fpage>
            <page-range>803-20</page-range>
            <pub-id pub-id-type="pmid">27157931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulligan</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Prajapati</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches.</article-title>
            <source>Br J Radiol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>87</volume>
            <issue>1035</issue>
            <fpage>20130392</fpage>
            <pub-id pub-id-type="pmid">24588666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epelman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daneman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blaser</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ortiz-Neira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Konen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jarr&#x000ed;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>OM</given-names>
              </name>
            </person-group>
            <article-title>Differential diagnosis of intracranial cystic lesions at head US: correlation with CT and MR imaging.</article-title>
            <source>Radiographics</source>
            <year>2006</year>
            <season>Jan-Feb</season>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>173</fpage>
            <page-range>173-96</page-range>
            <pub-id pub-id-type="pmid">16418251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Traughber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muzic</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>The role of imaging in radiation therapy planning: past, present, and future.</article-title>
            <source>Biomed Res Int</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>231090</fpage>
            <pub-id pub-id-type="pmid">24812609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanakita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takayanagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukasa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tago</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Igaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The long-term outcomes of radiosurgery for intracranial hemangioblastomas.</article-title>
            <source>Neuro Oncol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-33</page-range>
            <pub-id pub-id-type="pmid">24335701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niranjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Leksell Radiosurgery for the 3 H Tumors: Hemangiomas, Hemangioblastomas, and Hemangiopericytomas.</article-title>
            <source>Prog Neurol Surg</source>
            <year>2019</year>
            <volume>34</volume>
            <fpage>223</fpage>
            <page-range>223-231</page-range>
            <pub-id pub-id-type="pmid">31096251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoo</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Marianayagam</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pollom</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Meola</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic Radiosurgery for Cranial and Spinal Hemangioblastomas: A Single-Institution Retrospective Series.</article-title>
            <source>Neurosurgery</source>
            <year>2024</year>
            <month>Mar</month>
            <day>01</day>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>630</fpage>
            <page-range>630-642</page-range>
            <pub-id pub-id-type="pmid">37967154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>D'Astous</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tayag</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Pangilinan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Image-guided stereotactic radiosurgery for treatment of spinal hemangioblastoma.</article-title>
            <source>Neurosurg Focus</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>E12</fpage>
            <pub-id pub-id-type="pmid">28041328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Niranjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mongia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kondziolka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flickinger</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>The role of stereotactic radiosurgery for intracranial hemangioblastomas.</article-title>
            <source>Neurosurgery</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>443</fpage>
            <page-range>443-50; discussion 450-1</page-range>
            <pub-id pub-id-type="pmid">18812955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jabarkheel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis.</article-title>
            <source>J Neurooncol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">29204841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-167306.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asthagiri</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Zach</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Butman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Camphausen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lonser</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease.</article-title>
            <source>Neuro Oncol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-6</page-range>
            <pub-id pub-id-type="pmid">20150370</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
